Amin Sharifan, PharmD
Wissenschaftlicher Mitarbeiter - Department für Evidenzbasierte Medizin und Evaluation
-
amin.sharifan@donau-uni.ac.at
-
+43 2732 893-5399
-
Zum Kontaktformular
- Universität für Weiterbildung Krems
- Department für Evidenzbasierte Medizin und Evaluation
- Dr.-Karl-Dorrek-Straße 30
- 3500 Krems
- Österreich
Funktionen
Amin Sharifan ist als wissenschaftlicher Mitarbeiter und PhD-Student für Projekte im Bereich der evidenzbasierten Medizin zuständig.
Projekte (Auszug Forschungsdatenbank)
Laufende Projekte
Projektzeitraum: 01.08.2025–31.01.2026
Projektverantwortung (Universität für Weiterbildung Krems): Gerald Gartlehner
Projektzeitraum: 01.08.2025–31.01.2026
Projektverantwortung (Universität für Weiterbildung Krems): Gerald Gartlehner
Projektzeitraum: 15.07.2025–28.02.2026
Projektverantwortung (Universität für Weiterbildung Krems): Andreea Dobrescu
Fördergeber: andere internationale Organisationen
Projektzeitraum: 01.07.2025–30.06.2026
Projektverantwortung (Universität für Weiterbildung Krems): Andreea Dobrescu
Fördergeber: andere internationale Organisationen
Projektzeitraum: 01.04.2025–31.03.2028
Projektverantwortung (Universität für Weiterbildung Krems): Amin Sharifan
Fördergeber: Bundesländer (inkl. deren Stiftungen und Einrichtungen)
Evidence Review on Pharmacologic Treatment of Chronic Insomnia
Projektzeitraum: 01.03.2025–28.02.2027
Projektverantwortung (Universität für Weiterbildung Krems): Andreea Dobrescu
Fördergeber: Sonstige
Projektzeitraum: 01.11.2024–30.04.2025
Projektverantwortung (Universität für Weiterbildung Krems): Andreea Dobrescu
Abgeschlossene Projekte
Update of a Rapid Review on Outpatient Treat-ment of Confirmed COVID-19 (Version 3)
Projektzeitraum: 01.09.2024–31.12.2025
Projektverantwortung (Universität für Weiterbildung Krems): Isolde Sommer
Fördergeber: Sonstige
Projektzeitraum: 01.12.2024–30.09.2025
Projektverantwortung (Universität für Weiterbildung Krems): Gerald Gartlehner
Interpretation of Non-significant Differences
Projektzeitraum: 01.12.2022–31.12.2024
Projektverantwortung (Universität für Weiterbildung Krems): Gerald Gartlehner
Publikationen (Auszug Forschungsdatenbank)
Kang, J.; et. al.; Sharifan, A. (2026). Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study. Nature Medicine, 32: 527-544
Oh, J.; et. al.; Sharifan, A. (2026). Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990–2023: a Global Burden of Disease study. Nature Medicine, 32: 197-223
Sharifan, A. (2026). Misrepresentation of nonsignificant results: reporting pitfalls in urology randomised trials. BJU International, https://doi.org/10.1111/bju.70139: https://doi.org/10.1111/bju.70139
Sommer, I. Dobrescu, A. Gadinger, A. Sharifan, A. Pinte, L. Fangmeyer, M. Klerings, I. Gartlehner, G. (2026). Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Review for the American College of Physicians (Version 3). Annals of Internal Medicine, Online ahead of print: 10.7326/ANNALS-25-03691.
Ryan-Vig, S.; Sharifan, A. (2026). For people undergoing first-line treatment for advanced pancreatic cancer, how do gemcitabine-containing dual chemotherapy regimens compare with gemcitabine alone? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4689: https://doi.org/10.1002/cca.4689
Sharifan, A. (2026). For adults with obesity, what are the benefits and harms of semaglutide injections compared with liraglutide injections? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4732: https://doi.org/10.1002/cca.4732
Sharifan, A. (2026). In children with nocturnal enuresis, how does desmopressin therapy alone compare with desmopressin combination therapy (adding alarm therapy or other medications, such as anticholinergics or tricyclics)? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4711: https://doi.org/10.1002/cca.4711
Sharifan, A. (2026). For people undergoing first-line treatment for advanced pancreatic cancer, how do different chemotherapy combinations compare with gemcitabine plus nab-paclitaxel? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4691: https://doi.org/10.1002/cca.4691
Sharifan, A. (2026). In children with nocturnal enuresis, how does desmopressin compare with no treatment or placebo, alarm therapy, or other medications such as tricyclics, anticholinergics, or non-steroidal anti-inflammatory drugs? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4710: https://doi.org/10.1002/cca.4710
Sharifan, A. (2026). What are the benefits and harms of weekly SARS-CoV-2 testing compared with no routine testing for residents and healthcare workers in long-term care facilities? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4722: https://doi.org/10.1002/cca.4722
Sharifan, A. (2026). For adults with obesity, what are the benefits and harms of once-weekly tirzepatide injections compared with placebo? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4733: https://doi.org/10.1002/cca.4733
Sharifan, A. (2026). For adults with obesity, what are the benefits and harms of daily liraglutide injections compared with placebo? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4735: https://doi.org/10.1002/cca.4735
Sharifan, A. (2026). For the prevention of respiratory syncytial virus (RSV) disease in infants and children, what are the benefits and harms of maternal vaccination during pregnancy, and infant or child vaccination? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4715: https://doi.org/10.1002/cca.4715
Sharifan, A. (2026). Among healthy women of childbearing age who are not pregnant, what are the benefits and harms of respiratory syncytial virus (RSV) recombinant F nanoparticle vaccine compared with placebo? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4716: https://doi.org/10.1002/cca.4716
Sharifan, A. (2026). What are the benefits and harms of riboflavin supplements (vitamin B2) for lowering blood pressure in adults? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4727: https://doi.org/10.1002/cca.4727
Sharifan, A. (2026). For adults with obesity, what are the benefits and harms of once-weekly tirzepatide injections compared with once-weekly semaglutide injections? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4734: https://doi.org/10.1002/cca.4734
Sharifan, A. (2026). Among older adults (aged = 60 years), what are the benefits and harms of respiratory syncytial virus (RSV) vaccines (either RSV prefusion vaccines or RSV postfusion F protein-based vaccines) compared with placebo? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4714: https://doi.org/10.1002/cca.4714
Abdulazeem, H.; Borges do Nascimento, I.J.; Weerasekara, I.; Sharifan, A.; Grandi Bianco, V.; Cunningham, C.; Kularathne, I.; Deeken, G.; de Barros, J.; Sathian, B.; Østengaard, L.; Lamontagne-Godwin, F.; van Hoof, J.; Lazeri, L.; Redlich, C.; Marston, H.R.; Alistair Dos Santos, R.; Azzopardi-Muscat, N.; Yon, Y.; Novillo-Ortiz, D. (2025). Use of Digital Health Technologies for Dementia Care: Bibliometric Analysis and Report. JMIR Ment Health, 12:e64445: 10.2196/64445
Borges do Nascimento, I.J.; Abdulazeem, H.M.; Weerasekara, I.; Sharifan, A.; Grandi Bianco, V.; Kularathne, I.; Cunningham, C.; Sathian, B.; Deeken, G.; Østengaard, L.; Frederique-Djurdjevic, R.; van Hoof, J.; Lazeri, L.; Redlich, C.; Marston, H.R.; Sernizon uimarães, N.; de Barros, J.; dos Santos, R.A.; Azzopardi-Muscat, N.; Yon, Y.; (2025). An Overview of Reviews on Telemedicine and Telehealth in Dementia Care: Mixed Methods Synthesis An Overview of Reviews on Telemedicine and Telehealth in Dementia Care: Mixed Methods Synthesis. JMIR Mental Health, 12: e75266
Dobrescu, A.; Nussbaumer-Streit, B.; Wagner, G.; Sharifan, A.; Gadinger, A.; Klerings, I.; Nowak, C.; Gartlehner, G. (2025). Assessing the Impact of Unpublished Data on Network Meta-Analysis Outcomes in Outpatient Adults with Acute Migraine: A Study within a Review. Journal of Clinical Epidemiology, 112014: https://doi.org/10.1016/j.jclinepi.2025.112014
Tags